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Summary Background In the international, phase III, ran-
domized, double-blind CORRECT trial, regorafenib signifi-
cantly prolonged overall survival (OS) versus placebo in
patients with metastatic colorectal cancer (mCRC) that had
progressed on all standard therapies. This post hoc analysis
evaluated the efficacy and safety of regorafenib in Japanese
and non-Japanese subpopulations in the CORRECT trial.
Methods Patients were randomized 2 : 1 to regorafenib
160 mg once daily or placebo for weeks 1–3 of each 4-week
cycle. The primary endpoint was OS. Outcomeswere assessed
using descriptive statistics. ResultsOne hundred Japanese and
660 non-Japanese patients were randomized to regorafenib
(n=67 and n=438) or placebo (n=33 and n=222). Regorafe-
nib had a consistent OS benefit in the Japanese and non-
Japanese subpopulations, with hazard ratios of 0.81 (95 %
confidence interval [CI] 0.43–1.51) and 0.77 (95 % CI 0.62–
Electronic supplementary material The online version of this article
(doi:10.1007/s10637-014-0154-x) contains supplementary material,
which is available to authorized users.
T. Yoshino (*)
Department of Gastroenterology and Gastrointestinal Oncology,
National Cancer Center Hospital East, 6-5-1, Kashiwanoha,
Kashiwa 277-8577, Chiba, Japan
e-mail: tyoshino@east.ncc.go.jp
Y. Komatsu
Department of Cancer Chemotherapy, Hokkaido University Hospital
Cancer Center, Sapporo, Japan
Y. Yamada
Gastrointestinal Oncology Division, National Cancer Center
Hospital, Tokyo, Japan
K. Yamazaki
Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi-cho,
Sunto-gun, Shizuoka, Japan
A. Tsuji
Department of Medical Oncology, Kochi Health Sciences Center,
Kochi, Japan
T. Ura
Department of Clinical Oncology, Aichi Cancer Center Hospital,
Chikusa-ku, Nagoya, Aichi, Japan
A. Grothey
Department of Oncology, Mayo Clinic, Rochester, MN, USA
E. Van Cutsem
Digestive Oncology, University Hospitals and KU Leuven, Leuven,
Belgium
A. Wagner
Global Clinical Development–Oncology, Bayer Pharma AG, Berlin,
Germany
F. Cihon
Global Biostatistics, Bayer HealthCare Pharmaceuticals, Whippany,
NJ, USA
Y. Hamada
Medical Affairs, Oncology & Hematology, Bayer Yakuhin Ltd,
Osaka, Japan
A. Ohtsu
Exploratory Oncology Research & Clinical Trial Center, National
Cancer Center Hospital East, Kashiwa, Chiba, Japan
Present Address:
A. Tsuji
Kobe City Hospital Organization, Kobe CityMedical Center General
Hospital, Kobe, Japan
Invest New Drugs (2015) 33:740–750
DOI 10.1007/s10637-014-0154-x
0.94), respectively. Regorafenib-associated hand–foot skin
reaction, hypertension, proteinuria, thrombocytopenia, and
lipase elevations occurred more frequently in the Japanese
subpopulation than in the non-Japanese subpopulation, but
were generally manageable. Conclusion Regorafenib appears
to have comparable efficacy in Japanese and non-Japanese
subpopulations, with a manageable adverse-event profile,
suggesting that this agent could potentially become a standard
of care in patients with mCRC.
Keywords Regorafenib . Protein kinase inhibitors .
Japanese . Colorectal cancer . Clinical trial . Phase III
Introduction
Colorectal cancer (CRC) is the second most common cancer
in Japan, with estimated age-standardized incidence and mor-
tality rates of 32.2 and 11.9 per 100,000 population, respec-
tively, in 2012 [1]. An estimated 1.4 million new cases of
CRC occur worldwide each year, with almost 700,000 deaths
attributed to the disease, resulting in CRC being one of the
most important malignancies in the world [1].
More than 40 % of patients in Japan have locally advanced
or metastatic CRC (mCRC) at diagnosis [2], for which stan-
dard therapy generally consists of chemotherapy based on a
fluoropyrimidine plus either oxaliplatin or irinotecan, com-
bined with anti-vascular endothelial growth factor (VEGF)
therapy such as bevacizumab or ziv-aflibercept. Patients with
KRAS wild-type tumors also receive cetuximab or
panitumumab [3–5]. However, until recently, no further op-
tions were available for patients whose disease progressed on
available standard therapies.
Regorafenib is an orally administered multikinase inhibitor
that blocks the activity of a number of protein kinases associ-
ated with angiogenesis (VEGF receptors 1–3 and TIE2),
oncogenesis (KIT, RET, RAF1, BRAF, and BRAF V600E)
and the tumor microenvironment (platelet-derived growth
factor receptor and fibroblast growth factor receptor) [6].
The international multicentre, phase III CORRECT (patients
with metastatic COloRectal cancer treated with REgorafenib
or plaCebo after failure of standard Therapy) trial compared
regorafenib with placebo in patients with mCRC that had
progressed on all available standard therapies or who were
unable to tolerate standard therapies [7]. On the basis of the
results of CORRECT, regorafenib was approved for the treat-
ment of mCRC that has progressed on standard therapy by the
US Food and Drug Administration in September 2012 [8], by
the Japanese Ministry of Health, Labor, and Welfare in March
2013 [9], and by the European Medicines Agency in August
2013 [10].
CORRECT met its primary endpoint at a planned, formal
interim analysis, with an overall survival (OS) hazard ratio
(HR) for regorafenib versus placebo of 0.77 (95 % confidence
interval [CI] 0.64–0.94; one-sided p=0.0052) [7].
Progression-free survival (PFS) was also significantly greater
in the regorafenib group than in the placebo group (HR 0.49,
95 % CI 0.42–0.58; one-sided p<0.0001). Furthermore, rego-
rafenib showed OS and PFS benefit in both KRAS-wild-type
and KRAS-mutant tumor subgroups [7].
Previous trials of kinase inhibitors have shown differing
adverse-event profiles in Japanese and non-Japanese patients.
Subpopulation analyses of two international phase III studies
comparing axitinib versus sorafenib and everolimus versus
placebo in patients with metastatic renal cancer showed that
Japanese patients had higher rates of several adverse events,
including hand–foot skin reaction (HFSR), than the overall
trial population [11, 12]. Therefore, it was felt to be important
to investigate the safety and efficacy profile of regorafenib in
Japanese and non-Japanese patients in the CORRECT trial.
This post hoc analysis was conducted to assess the efficacy,
safety, population pharmacokinetics (PK), and quality-of-life
(QoL) effects of regorafenib in the Japanese and non-Japanese
subpopulations in the CORRECT trial. In addition, the poten-
tial relationship between patients’ baseline body size and the
occurrence of regorafenib-associated adverse events was
assessed.
Materials and methods
CORRECT was a phase III, randomized, double-blind,
placebo-controlled trial involving 114 centers in 16 countries.
Eligibility criteria, treatment schedule, endpoints, and statisti-
cal analysis criteria have been reported in detail previously [7].
Included patients were aged at least 18 years and had mCRC
that had progressed during or within 3 months after the last
dose of all available standard therapies for mCRC. Patients
were randomized 2 : 1 to receive regorafenib 160 mg or
placebo once daily for weeks 1–3 of each 4-week cycle, in
combination with best supportive care. The primary endpoint
of the trial was OS (time from randomization to death from
any cause), while secondary efficacy endpoints included PFS
(time from randomization to first radiological or clinical pro-
gression or death from any cause), objective response rate
(ORR), and disease control rate (DCR). Safety, health-
related QoL, and PK were also assessed. The trial required
582 deaths for the final analysis. The first formal interim
analysis, to assess futility, was conducted when approximately
30% of the expected total number of deaths had occurred. The
second interim analysis, at about 70 % of the total expected
deaths, evaluated both efficacy and futility. Monitoring
boundaries were based on prespecifiedO’Brien–Fleming-type
stopping boundaries. The primary and secondary efficacy
time-to-event endpoints for the overall population were ana-
lyzed using a one-sided log-rank test stratified by the same
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stratification factors as at randomization. The trial was regis-
tered at ClinicalTrials.gov, identifier NCT01103323.
Post hoc subpopulation analyses performed for Japanese
and non-Japanese patients presented here were descriptive in
nature, using Kaplan–Meier (KM) estimates and KM curves
to analyze time-to-event parameters, such as OS and PFS. HR
estimates with 95 % CIs were determined on the basis of an
unstratified Cox regression model. For the subpopulation
analyses, a HR (regorafenib over placebo) of less than 1
suggested a beneficial effect favoring regorafenib, whereas a
HR of greater than 1 suggested an effect favoring placebo.
Health-related QoL was measured using the cancer-
specific European Organisation for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire core-30
(QLQ-C30) [13], and the general-health EuroQol 5-
dimension (EQ-5D) health utility index and visual analog
scale (VAS) [14]. An analysis-of-covariance model was used
to examine the time-adjusted area under the curve (AUC) of
the EORTC QLQ-C30 global health status, EQ-5D health
utility index, and EQ-5D VAS scores, with least-squares
(LS) mean time-adjusted AUCs and 95 % CIs estimated for
each treatment group and for the difference between treatment
groups. QoL outcomes were also compared using descriptive
statistics.
Blood samples for PK analysis were collected on day 15 of
cycle 1 before administration of study drug, 2–4 h after
administration, and 5–10 h after administration. The PK of
regorafenib and its pharmacologically active metabolites, M2
(N-oxide metabolite) and M5 (N-oxide/N-desmethyl metabo-
lite), were analyzed using a population PK model based on
data collected during earlier studies of regorafenib. Regorafe-
nib and metabolite PK data were pooled with concentration
data from other studies of regorafenib monotherapy and ana-
lyzed using non-linear mixed-effects modeling. PK data were
evaluated with historical data, without formal statistical
analysis.
Results
Patient demographics and baseline disease characteristics
Results are based on the planned, formal interim analysis
database, considered the final formal and definitive results,
where the CORRECT trial met its primary endpoint showing
that the regorafenib group had a statistically significant im-
provement in OS compared with placebo. A total of 933 non-
Japanese patients were screened for inclusion at 95 centers in
15 countries between 30 April 2010 and 22 March 2011; of
these, 660 patients were randomized to treatment with rego-
rafenib (n=438) or placebo (n=222), while 656 received at
least one dose of study treatment and were included in the
safety population (regorafenib n=435, placebo n=221). The
ethnicity of the non-Japanese subpopulation consisted of 593
white, 14 black or African American, 11 non-Japanese Asian,
and 42 other or not reported. A total of 119 Japanese patients
were screened for inclusion at 19 centers in Japan between 17
November 2010 and 10 February 2011; of these, 100 patients
were randomized to treatment with regorafenib (n=67) or
placebo (n=33), while 97 received at least one dose of study
treatment and were included in the safety population (regoraf-
enib n=65, placebo n=32). The flow of patients in the Japa-
nese subpopulation through the trial is shown in Online Re-
source 1 (Fig. S1).
In general, the baseline characteristics of the Japanese
subpopulation were similar to those of the non-Japanese sub-
population (Table 1), with the exception of lower median
bodyweight, lower median body-mass index (BMI), and a
slightly greater proportion of patients with an Eastern Coop-
erative Oncology Group (ECOG) performance status of 0 in
the Japanese subpopulation than in the non-Japanese
subpopulation.
Treatment
Drug exposure in Japanese and non-Japanese subpopulations
is shown in Table 2. The mean±standard deviation (SD)
overall duration of regorafenib treatment (including time off
drug and dose interruptions) was 10.3±7.9 weeks (median
7.3; range 0.3–28.9) in the Japanese subpopulation and 12.3±
10.0 weeks (median 7.3; range 0.3–47.0) in the non-Japanese
subpopulation. The mean±SD daily dose of regorafenib was
142.2±20.2 mg (median 152.7; range 91.1–160.0) and 147.9
±18.3 mg (median 160.0; range 85.7–160.0), respectively.
Mean±SD regorafenib dose intensity, defined as the pro-
portion of planned dose received, was 69.3±21.2 % (me-
dian 71.4; range 9.5–100.0) in the Japanese subpopula-
tion and 80.4±19.3 % (median 83.3; range 9.5–114.3)
in the non-Japanese population.
Regorafenib dose modifications due to drug-associated
adverse events were more frequent in the Japanese than in
the non-Japanese subpopulation, being reported in 84.6 and
51.3 % of patients, respectively. Rates of regorafenib discon-
tinuation due to drug-associated adverse events were higher in
the Japanese than in the non-Japanese subpopulation, but still
low in both subpopulations (13.8 and 7.4 %, respectively).
Drug exposure in the Japanese and non-Japanese subpop-
ulations receiving placebo (in terms of overall duration of
treatment, actual daily dose, dose intensity, and discontinua-
tion due to drug-related adverse events) was similar.
Efficacy
The HR for OS in the regorafenib group vs placebo was 0.81
(95 % CI 0.43–1.51) in the Japanese subpopulation and 0.77
(95 % CI 0.62–0.94) in the non-Japanese subpopulation, with
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Table 1 Baseline demographics and characteristics of the Japanese and non-Japanese patient subpopulations in the CORRECT trial
Japanese subpopulation Non-Japanese subpopulation
Regorafenib (n=67) Placebo (n=33) Regorafenib (n=438) Placebo (n=222)
Median age (range), years 63 (44–79) 61 (34–75) 61 (22–82) 61 (25–85)
Sex, n (%)
Men 47 (70) 16 (49) 264 (60) 137 (62)
Women 20 (30) 17 (52) 174 (40) 85 (38)
Median bodyweight (range), kg 62.6 (35.5–108.0) 58.2 (34.0–89.7) 73.5 (38.5–169.6) 77.0 (43.0–156.0)
Median body mass index (range), kg/m2 23.7 (15.4–34.3) 22.9 (13.9–29.9) 25.0 (14.4–47.3) 26.2 (17.2–50.4)
ECOG performance status, n (%)
0 41 (61) 24 (73) 224 (51) 122 (55)
1 26 (39) 9 (27) 214 (49) 100 (45)
Primary site of disease, n (%)
Colon 37 (55) 15 (46) 286 (65) 157 (71)
Rectum 28 (42) 18 (55) 123 (28) 51 (23)
Colon and rectum 2 (3) 0 28 (6) 14 (6)
Number of previous systemic anticancer therapies for metastatic disease, n (%)
1–2 17 (25) 5 (15) 118 (27) 58 (26)
3 20 (30) 7 (21) 105 (24) 65 (29)
≥4 30 (45) 21 (64) 215 (49) 99 (45)
Time from diagnosis of metastatic disease to randomization, n (%)
<18 months 8 (12) 2 (6) 83 (19) 47 (21)
≥18 months 59 (88) 31 (94) 355 (81) 175 (79)
KRAS mutation, n (%)
No 26 (39) 18 (55) 179 (41) 76 (34)
Yes 39 (58) 14 (42) 234 (53) 143 (64)
Unknown 2 (3) 1 (3) 25 (6) 3 (1)
Abbreviation: ECOG, Eastern Cooperative Oncology Group
Table 2 Drug exposure in Japanese and non-Japanese patients
Japanese subpopulation Non-Japanese subpopulation
Regorafenib (n=65) Placebo (n=32) Regorafenib (n=435) Placebo (n=221)
Overall duration of treatment,a weeks
Mean±SD 10.3±7.9 7.3±4.7 12.3±10.0 7.9±5.3
Median (range) 7.3 (0.3–28.9) 7.0 (0.6–22.9) 7.3 (0.3–47.0) 7.0 (0.6–38.6)
Actual daily dose, mg
Mean±SD 142.2±20.2 158.3±9.4 147.9±18.3 159.4±3.8
Median (range) 152.7 (91.1–160.0) 160.0 (107.0–160.0) 160.0 (85.7–160.0) 160.0 (121.6–160.0)
Dose intensity (%)
Mean±SD 69.3±21.2 89.1±17.7 80.4±19.3 90.3±16.1
Median (range) 71.4 (9.5–100.0) 98.8 (19.1–100.0) 83.3 (9.5–114.3) 100.0 (19.1–100.0)
Patients with drug-related adverse events leading to:
Dose modification,bn (%) 55 (84.6) 6 (18.8) 223 (51.3) 17 (7.7)
Permanent discontinuation, n (%) 9 (13.8) 0 32 (7.4) 3 (1.4)
a Includes time off drug and dose interruptions
b Includes dose interruptions and reductions
Abbreviation: SD, standard deviation
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no apparent difference between subpopulations (Fig. 1a and
c). The median OS in the regorafenib group was 6.6 months
(range 0.2–7.5) in the Japanese subpopulation and 6.2 months
(range 0.2–13.2) in the non-Japanese subpopulation, while
median OS in the placebo group was 7.0 months (range
0.03–7.5) in the Japanese population and 4.9 months (range
0.4–13.6) in the non-Japanese subpopulation.
In both the Japanese and the non-Japanese subpopulations,
PFS was greater in regorafenib-treated patients than in place-
bo recipients, with HRs of 0.47 (95 % CI 0.30–0.74) and
0.50(95 % CI 0.42–0.60), respectively (Fig. 1b and d). The
median PFS in regorafenib recipients was 1.9 months (range
0.03–5.7) in the Japanese subpopulation and 1.9 months
(range 0.03–11.1) in the non-Japanese subpopulation, while
median PFS in the placebo groups was 1.7 months (range
0.03–5.2) and 1.7 months (range 0.03–9.1) in the Japanese
and non-Japanese subpopulations, respectively.
In the regorafenib group, DCRs of 40 and 41 % were
observed in the Japanese and non-Japanese subpopulations,
respectively, compared with 15 % in both Japanese and non-
Japanese subpopulations in the placebo group. Overall re-
sponse was similar in the regorafenib and placebo groups,
with ORRs of 2 and 1 % reported in the regorafenib-treated
Japanese and non-Japanese subpopulations, respectively,
consisting of partial responses in one Japanese patient and
four non-Japanese patients. Among placebo recipients, no
responses were reported in the Japanese subpopulation and
one partial response (<1 %) was reported in the non-Japanese
subpopulation. Reduction in tumor volume from baseline was
observed in 33 % and 27 % of the regorafenib-treated Japa-
nese and non-Japanese subpopulations, respectively. Changes
in target lesion size in the Japanese and non-Japanese subpop-
ulations are shown in Fig. 2.
Safety
In the Japanese and non-Japanese subpopulations, treatment-
related adverse events of any grade were observed in 99 and
92 % of regorafenib-treated patients, respectively, and in 59
and 61 % of placebo recipients, respectively (Table 3). Grade
3 or greater treatment-associated adverse events were reported
in 80 and 51 % of regorafenib-treated patients, respectively,
and 22 and 13 % of placebo recipients, respectively. No clear
relationship was found between the incidence of regorafenib-
associated adverse events and baseline BMI in the Japanese
and non-Japanese subpopulation (Table 4).
Regorafenib-associated adverse events of any grade occur-
ring at a rate at least 20 % greater in the Japanese subpopula-
tion than in the non-Japanese subpopulation were HFSR (80
vs 42 %), hypertension (60 vs 23 %), proteinuria (40 vs
2 %), thrombocytopenia (39 vs 9 %) and lipase elevations (25
vs 2 %). In contrast, the incidence of diarrhea was lower in the
Japanese subpopulation than in the non-Japanese subpopula-
tion (any grade: 22 vs 36 %; grade ≥3: 2 vs 8 %).
Serious drug-associated adverse events were reported in 9
and 12 % of the regorafenib-treated Japanese and non-
Fig. 1 Kaplan–Meier curves showing overall survival and progression-free survival in Japanese (a and b, respectively) and non-Japanese patients (c and
d, respectively)
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Japanese subpopulations, respectively, compared with 9 and
3 % of the Japanese and non-Japanese subpopulation receiv-
ing placebo, respectively. The most frequent regorafenib-
associated serious adverse event in the Japanese subpopula-
tion was anorexia, reported in three patients (5 %).
Regorafenib-associated liver function adverse events were
reported more frequently in the Japanese subpopulation than
in the non-Japanese subpopulation, although the incidence of
grade 3–4 liver events was low in both subpopulations. Ala-
nine aminotransferase (ALT) elevations were reported in 12%
and fewer than 1 % of the regorafenib-treated Japanese and
non-Japanese subpopulations, respectively, aspartate amino-
transferase (AST) elevations in 19 and 2 %, respectively, and
bilirubin elevations in 15 and 8 %, respectively. One case of
lethal liver dysfunction related to regorafenib was observed in
the Japanese subpopulation. The patient was a 62-year-old
manwith liver metastases and an ECOGperformance status of
0 at trial entry. Forty-three days after starting regorafenib
treatment, the patient presented with grade 3 jaundice and
grade 2 liver dysfunction, and regorafenib treatment was
permanently discontinued the following day. Laboratory test
results showed elevated alkaline phosphatase (634 U/L; local
laboratory range not provided), total bilirubin (7.7×upper
limit of normal [ULN] [9.2 mg/dL]), AST (30.8×ULN
[1261 U/L]) and ALT (31×ULN [1393 U/L]). The patient’s
platelet count was also depressed (91×103/mm3; range not
provided). The patient’s hepatitis status was confirmed as
negative. The severity of liver dysfunction increased to grade
5 at 43 days after treatment discontinuation.
Population pharmacokinetics
Data from 381 patients (Japanese n=41; non-Japanese n=
340) were included in the population PK analysis. The popu-
lation PK analysis was based on 3,696 data points from
samples collected before administration, 2–4 h after adminis-
tration, and 5–10 h after administration of regorafenib on day
15 of cycle 1. The analysis showed a similar distribution of
calculated AUC over a 24-h dosing interval and AUC from
the start of treatment until 24 h after the last dose for regoraf-
enib and its M2 and M5 metabolites in the Japanese and non-
Japanese subpopulations (Fig. 3 and Online Resource 1
[Table S1]).
Quality of life
LS mean time-adjusted AUCs of EORTC QLQ-C30 global
health status, EQ-5D health utility index, and EQ-5D VAS
scores did not differ between regorafenib and placebo groups
in either the Japanese or the non-Japanese subpopulation. QoL
scores appeared to be similar in the regorafenib and placebo
groups at baseline and at the end of treatment in both the
Japanese and non-Japanese subpopulations (Table 5).
Discussion
CORRECT is the first randomized, controlled, phase III trial
with a substantial number of Japanese patients to assess a new
therapeutic agent in mCRC, with previous international phase
III studies in this field including only a small number of
Japanese patients or none at all. In this analysis, the primary
endpoint of OS appeared similar in the Japanese and non-
Japanese subpopulations, with HRs (regorafenib over place-
bo) of 0.81 and 0.77, respectively. Regorafenib was also
associated with a greater improvement in PFS and higher
DCRs than placebo, with consistent benefits in both the Jap-
anese and the non-Japanese subpopulations.
The adverse-event profile of regorafenib in the Japanese
subpopulation differed from that observed in the non-Japanese
subpopulation, with a higher incidence of HFSR, hyperten-
sion, proteinuria, thrombocytopenia, and lipase elevations,
and a lower incidence of diarrhea seen in the former group.
The incidence of grade 3 or greater treatment-associated ad-
verse events was higher in the Japanese than in the non-
Japanese subpopulation, although serious regorafenib-
associated adverse events were reported at similar rates in
both subpopulations (9 vs 12 %, respectively) and no unex-
pected safety signals were observed in either. A higher inci-
dence of HFSR in Japanese versus non-Japanese patients has
been noted in previous clinical trials of other kinase inhibitors
[11], as has a lower incidence of treatment-related diarrhea in
Fig. 2 Maximum percentage change in target lesion size in (a) Japanese
patients and (b) non-Japanese patients
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Japanese versus non-Japanese patients with mCRC receiving
fluoropyrimidine alone or in combination with irinotecan [15,
16]. Investigation of the relationships between the incidence
of regorafenib-associated adverse events and BMI or body
surface area in the Japanese and non-Japanese subpopulations
found no clear trends (body surface area data not shown).
Previous anti-epidermal growth factor receptor or capecita-
bine treatment also showed no relationship with regorafenib-
associated HFSR in both the Japanese and the non-Japanese
subpopulations (data not shown). Further investigation is
needed to clarify the reasons for the higher incidence of
HFSR, as well as other differences in adverse-event profile,
in the Japanese versus the non-Japanese subpopulation.
One Japanese patient developed fatal liver dysfunction
associated with regorafenib treatment, with onset 43 days after
starting regorafenib, and death occurring 86 days after initia-
tion of regorafenib. Overall, elevation of ALT, AST and bili-
rubin levels appeared to occur more frequently in the Japanese
subpopulation than in the non-Japanese subpopulation, al-
though rates of grade 3 or greater elevations appeared gener-
ally similar between subpopulations. Frequent and careful
monitoring of liver function is advisable, especially during
the first two cycles of treatment, because this period is when
liver-function abnormalities occurred most frequently in our
study.
Corresponding to the higher rate of adverse events ob-
served in the Japanese subpopulation than in the non-
Japanese subpopulation, dose modifications due to adverse
events were more frequent in the regorafenib-treated Japanese
subpopulation than in the non-Japanese subpopulation (84.6
vs 51.3 %, respectively), leading to the lower mean dose
intensity in the former than in the latter group (69.3 vs.
80.4 %, respectively).
Rates of treatment discontinuation because of regorafenib-
associated adverse events were higher in the Japanese sub-
population than in the non-Japanese subpopulation (13.8 vs
7.4 %, respectively). This difference might be due to
interpatient PK variability; however, the regorafenib dose
and schedule (160 mg once daily for the first 3 weeks of each
4-week cycle) that was selected as the recommended dose for
further study in phase III trials, including CORRECT [7], was
based on findings in a phase I trial in non-Japanese patients
Table 3 Drug-related adverse events reported in ≥10 % of patients receiving regorafenib or placebo in the Japanese and non-Japanese subpopulations
Japanese subpopulation, n (%) Non-Japanese subpopulation, n (%)
Regorafenib (n=65) Placebo (n=32) Regorafenib (n=435) Placebo (n=221)
Adverse event, n (%) Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3
Any adverse event 64 (99) 52 (80) 19 (59) 7 (22) 401 (92) 223 (51) 135 (61) 28 (13)
Hand–foot skin reaction 52 (80) 18 (28) 1 (3) 0 181 (42) 65 (15) 18 (8) 1 (<1)
Hypertension 39 (60) 7 (11) 1 (3) 0 100 (23) 29 (7) 14 (6) 2 (<1)
Anorexia 28 (43) 6 (9) 8 (25) 3 (9) 124 (29) 10 (2) 31 (14) 4 (2)
Fatigue 28 (43) 5 (8) 8 (25) 3 (9) 209 (48) 43 (10) 63 (29) 10 (5)
Proteinuria 26 (40) 4 (6) 2 (6) 0 9 (2) 3 (<1) 2 (<1) 1 (<1)
Thrombocytopenia 25 (39) 4 (6) 2 (6) 0 38 (9) 10 (2) 3 (1) 1 (<1)
Rash/desquamation 23 (35) 2 (3) 4 (13) 0 107 (25) 27 (6) 6 (3) 0
Voice changes 21 (32) 0 0 0 126 (29) 1 (<1) 14 (6) 0
Fever 17 (26) 2 (3) 1 (3) 0 35 (8) 2 (<1) 6 (3) 0
Lipase elevation 16 (25) 9 (14) 0 0 8 (2) 7 (2) 1 (<1) 1 (<1)
Diarrhea 14 (22) 1 (2) 2 (6) 0 155 (36) 35 (8) 19 (9) 2 (<1)
Hypophosphatemia 13 (20) 9 (14) 0 0 12 (3) 10 (2) 1 (<1) 1 (<1)
Oral mucositis 13 (20) 1 (2) 0 0 123 (28) 14 (3) 9 (4) 0
Aspartate aminotransferase elevation 12 (19) 4 (6) 1 (3) 0 7 (2) 2 (<1) 4 (2) 2 (<1)
Nausea 11 (17) 1 (2) 4 (13) 0 61 (14) 1 (<1) 24 (11) 0
Epistaxis 10 (15) 0 1 (3) 0 26 (6) 0 4 (2) 0
Hyperbilirubinemia 10 (15) 1 (2) 2 (6) 1 (3) 35 (8) 9 (2) 2 (<1) 1 (<1)
Weight loss 10 (15) 0 1 (3) 0 59 (14) 0 5 (2) 0
Amylase elevation 9 (14) 2 (3) 0 0 5 (1) 2 (<1) 0 0
Constipation 9 (14) 0 0 0 33 (8) 0 12 (5) 0
Alanine aminotransferase elevation 8 (12) 3 (5) 1 (3) 0 4 (<1) 2 (<1) 1 (<1) 0
Taste alteration 7 (11) 0 0 0 28 (6) 0 5 (2) 0
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[17, 18], which was confirmed by a Japanese phase I trial [19].
In addition, population PK analysis in the CORRECT trial
showed a similar distribution of regorafenib AUC over a 24-h
dosing period in the Japanese and non-Japanese subpopula-
tions. Further investigation is warranted to confirm the reason
for the differences in adverse-event profiles and treatment
tolerability between Japanese and non-Japanese populations.
Time-adjusted AUCs of the scores on the health-related
QoL instruments appeared to be generally similar in both
subpopulations, and did not differ significantly between rego-
rafenib and placebo recipients in either subpopulation. Fur-
thermore, differences between regorafenib and placebo were
below the minimum difference in scores considered to be
clinically meaningful [20, 21]. These findings indicate that,
despite a higher rate of adverse events compared with placebo,
regorafenib was not associated with clinically meaningful
impairment of QoL in either the Japanese or the non-
Japanese subpopulation.
It should be recognized that this subpopulation analysis has
some limitations. Firstly, this analysis was not prespecified,
although geographic differences were considered in the trial
design, and geographical region was a stratification factor
during randomization. Secondly, the Japanese subpopulation
represents only a small proportion (n=100) of the overall
patient population (n=760 total randomized patients) included
in the CORRECT trial; as a result, subpopulation analyses had
Fig. 3 Distribution of area under the concentration–time curve over a
24-h dosing interval (AUC0–24) of (a) regorafenib, (b) M2 and (c) M5 in
Japanese and non-Japanese patients. Boxes represent the median and
interquartile range of AUC0–24 of regorafenib, M2 and M5; whiskers
represent the range between the lowest and highest values within 1.5
times the first and third quartiles. Dots represent outlying values greater
than 1.5 times the third quartile
Table 5 Time-adjusted area under the curve (AUC) and change from baseline in health-related quality-of-life scores in Japanese and non-Japanese
patients
Outcome Japanese population Non-Japanese population
n Regorafenib (n=67) n Placebo (n=33) n Regorafenib (n=438) n Placebo (n=222)
EORTC QLQ-C30 global health status
Baseline, median (range) 65 75.0 (0.0, 100.0) 32 79.2 (16.7, 100.0) 411 66.7 (0.0, 100.0) 208 66.7 (0.0, 100.0)
End of treatment, median (range) 52 50.0 (0.0, 100.0) 30 50.0 (0.0, 91.7) 222 50.0 (0.0, 100.0) 114 50.0 (0.0, 100.0)
Time-adjusted AUC, LSM (95 % CI) 58.0 (53.1, 62.9) 57.7 (51.4, 63.9) 56.3 (52.0, 60.5) 57.7 (53.4, 62.0)
Difference from placebo 0.3 (−5.5, 6.2) – −1.4 (−3.5, 0.6) –
EQ-5D health utility index
Baseline, median (range) 64 0.8 (−0.1, 1.0) 31 0.9 (0.2, 1.0) 409 0.7 (−0.3, 1.0) 208 0.8 (−0.2, 1.0)
End of treatment, median (range) 51 0.7 (−0.4, 1.0) 29 0.7 (−0.4, 1.0) 221 0.7 (−0.6, 1.0) 114 0.7 (−0.3, 1.0)
Time-adjusted AUC, LSM (95 % CI) 0.7 (0.7, 0.8) 0.7 (0.6, 0.8) 0.6 (0.6, 0.7) 0.6 (0.6, 0.7)
Difference from placebo 0.0 (−0.0, 0.1) − −0.0 (−0.0, 0.0) −
EQ-5D VAS
Baseline, median (range) 65 75.0 (10.0, 100.0) 32 80.0 (30.0, 95.0) 406 69.0 (3.0, 100.0) 203 70.0 (4.0, 100.0)
End of treatment, median (range) 51 55.0 (4.0, 100.0) 30 60.0 (0.0, 99.0) 221 60.0 (0.0, 99.0) 113 60.0 (5.0, 100.0)
Time-adjusted AUC, LSM (95 % CI) 63.3 (59.2, 67.4) 65.7 (60.5, 70.9) 58.5 (54.5, 62.5) 59.5 (55.4, 63.7)
Difference from placebo −2.4 (−7.3, 2.5) − −1.1 (−3.0, 0.9) −
Abbreviations: CI, confidence interval; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
core-30; EQ-5D, EuroQol 5-Dimension; LSM, least-squares mean; VAS, visual analogue scale
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insufficient statistical power for any inferential analyses,
which needs to be taken into consideration when interpreting
the results. The trial was not designed to test for statistically
significant differences between treatment effects (i.e., regoraf-
enib vs placebo) in the Japanese and non-Japanese subpopu-
lations. However, this subpopulation analysis may provide a
clearer picture of the efficacy and safety of regorafenib in
Japanese patients than comparisons with historical controls
derived from other trials conducted in separate populations of
Japanese and non-Japanese patients. A phase III trial entitled
‘Asian subjects with mCRC treated with regorafenib or pla-
cebo after failure of standard therapy (CONCUR)’
(ClinicalTrials.gov identifier: NCT01584830) is providing
more robust efficacy and safety data for regorafenib in Asian
patients.
In conclusion, regorafenib appears to be as effective
in the Japanese subpopulation as it is in the non-
Japanese subpopulation. The adverse-event profile was
generally as expected in Japanese patients, although
there were some differences in the occurrence of certain
adverse events between the Japanese and non-Japanese
subpopulations. Adverse events were generally manage-
able with dose modifications, and durations of treatment
were similar in both subpopulations. On the basis of
these results, regorafenib has the potential to become a
standard of care for Japanese as well as non-Japanese
patients with mCRC.
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